Home

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

398.2

$million

Invested

92

innovative

Projects

12

different

Countries

12

human clinical

TRIALS

2

available

DIAGNOSTICS

2

advanced development

FUNDING

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2021-2022

Annual Report

Working Together to Address the Global Threat of Antimicrobial Resistance

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome. Watch this video on what CARB-X is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
Wellcome
UK Government
BARDA
NIAID

Alliance Partners

Bill and Melinda Gates Foundation

Events

Events

10.05.23

 

Canada Webinar

10.11.23

Boston 

ID Week 2023

10.15.23

 

World Health Summit 2023

CARB-X News

  • 08.21.2023  |  G20 Health Ministers highlight urgent need to develop new antimicrobials to tackle resistance full release

  • 08.10.2023  |  UK GOVERNMENT BOLSTERS PARTNERSHIP WITH CARB-X full release

  • 08.03.2023  |  GOVERNMENT OF CANADA TO JOIN CARB-X PARTNERSHIP full release

See All News

In The News

  • 08.27.2023  |  Superbugs: why it’s so hard to stop the ‘silent pandemic’ full story

  • 08.23.2023  |  CARB-X Receives Global Funding in Fight Against Antimicrobial Resistance full story

  • 07.28.2023  |  GARDP and Bugworks join forces to accelerate development of a novel antibiotic to treat serious bacterial infections full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.